New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTRBC, JNPR, RIG, MMYT, GCI, TEVA, LFL, EPDOn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 19, 2015
04:26 EDTRIGStocks with implied volatility movement; TSO RIG
Subscribe for More Information
February 18, 2015
14:18 EDTRIGTransocean February volatility increases into Q4 and outlook
Subscribe for More Information
10:05 EDTRIGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:45 EDTTEVAEagle Pharmaceuticals price target raised to $37 from $30 at Cantor
Subscribe for More Information
07:13 EDTTEVAEagle Pharmaceuticals target raised to $43 from $25 at William Blair
William Blair raised its price target for Eagle Pharmaceuticals (EGRX) to $43 saying the company's agreement with Teva (TEVA) removes a major overhang on the stock. William Blair says the deal is a significant positive for Eagle since it removes litigation risk and moves the company immediately into profitability. It keeps an Outperform rating on the stock.
06:56 EDTRIGTransocean initiated with an Underperform at BMO Capital
Subscribe for More Information
February 17, 2015
16:22 EDTRIGOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTRIGOptions Update; February 17, 2015
Subscribe for More Information
12:50 EDTRIGOn The Fly: Midday Wrap
Subscribe for More Information
10:06 EDTRIGTransocean falls after cutting dividend, CEO departure, levels to watch
Subscribe for More Information
08:47 EDTTEVABioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
08:39 EDTTEVATeva deal small but important, says BMO Capital
Subscribe for More Information
08:35 EDTTEVATeva announces launch of generic Lovenox and Zyvox in U.S.
Subscribe for More Information
07:04 EDTTEVATeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.
06:59 EDTRIGTransocean price target lowered to $6 from $16 at Deutsche Bank
Deutsche Bank lowered its price target for Transocean shares to $6 after the company announced an 80% dividend reduction and the departure of its CEO. Deutsche says reducing the dividend frees up about $800M per year and that the move will likely be viewed positively since an elimination was a potential outcome. The firm, however, expects the company's free cash flow to remain negative for the "foreseeable future" and reiterates a Sell rating on the stock. Shares of the offshore driller are trading up 55c to $19.60 in pre-market trading.
05:21 EDTRBCRegal-Beloit sees FY15 adjusted EPS $5.45-$5.85, consensus $5.50
Regal Chairman and CEO Mark Gliebe stated, "We are executing on the three-year plan we laid out for investors in December 2014. Current business conditions give us confidence in our North American operations but unfavorable currency translation, uncertainty in Europe and a decline in oil and gas investments will be headwinds in 2015. Despite these challenges, we continue to expect our margin improvement initiatives will enable us to achieve the first year targets for our legacy businesses that we communicated in December. We expect 2015 adjusted diluted EPS to be in the range of $5.45-$5.85, which includes accretion from the PTS acquisition."
05:20 EDTRBCRegal-Beloit reports Q4 adjusted EPS 82c, consensus 94c
Subscribe for More Information
February 16, 2015
15:17 EDTRIGTransocean slashes dividend to 60c from $3.00, says CEO leaving
Subscribe for More Information
14:25 EDTRIGTransocean to lower annual dividend to 60c per share
Subscribe for More Information
10:29 EDTRIGTransocean announces departure of CEO Steven Newman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use